AMGN Q1 2026 Earnings Call Summary

Amgen Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Product Sales: Amgen reported $8 billion in total product sales for Q1 2026, reflecting a 4% year-over-year growth.
Key Growth Drivers: Six key growth products accounted for 70% of sales, generating $5.6 billion with a combined growth of 24%.
Operating Margin: Non-GAAP operating margin was 45%, consistent with previous expectations.
Free Cash Flow: Generated $1.5 billion in free cash flow.
R&D Spending: Increased by 16% year-over-year, focusing on late-stage pipeline investments.
Dividend: Increased dividend by 6% to $2.52 per share.

2. Strategic Updates and Business Highlights

Growth Drivers: Key products like Repatha (34% growth), EVENITY (27% growth), and TEZSPIRE (20% growth) contributed significantly to sales.
Pipeline Developments:
- MariTide: Focused on obesity and type 2 diabetes, with new Phase III studies initiated to evaluate dosing schedules.
- Olpasiran: Progressing in Phase III for cardiovascular risk reduction.
- UPLIZNA: Strong growth in rare diseases, with a 188% increase in sales.
AI Integration: Continued advancements in AI for drug discovery and clinical trial efficiencies, with a focus on enhancing productivity across the organization.

3. Forward Guidance and Outlook

Revenue Guidance: Raised 2026 revenue expectations to between $37.1 billion and $38.5 billion.
Earnings Per Share: Non-GAAP EPS guidance increased to a range of $21.70 to $23.10.
Operational Expectations: Anticipated operating margin to remain around 45% to 46% for the full year.

4. Bad News, Challenges, or Points of Concern

Sales Erosion: Prolia and XGEVA saw a combined 32% decrease in sales, attributed to loss of exclusivity and increased competition from biosimilars.
Regulatory Concerns: The FDA proposed to withdraw approval for TAVNEOS, which could impact its market presence.
Tax Litigation: Ongoing disputes with the IRS regarding tax years 2010-2018 could have material financial implications if the IRS's draft calculations are upheld.

5. Notable Q&A Insights

MariTide Studies: Questions about the design of the SWITCH studies revealed a focus on switching patients from weekly injectables to less frequent dosing, with a primary endpoint of body weight change after 52 weeks.
Repatha’s Market Penetration: Strong growth in primary prevention was highlighted, with a significant increase in new-to-brand prescriptions.
IMDELLTRA’s Expansion: Discussion on moving IMDELLTRA into earlier lines of therapy and its selection for the FDA's real-time clinical trial pilot program.
Olpasiran’s Competitive Landscape: Confidence expressed in olpasiran’s unique efficacy in targeting Lp(a), independent of other therapies like GLP-1s and PCSK9 inhibitors.

Overall, Amgen's Q1 2026 performance reflects strong growth in key product areas and a robust pipeline, despite facing challenges from patent expirations and regulatory scrutiny. The company remains optimistic about its future growth trajectory and strategic initiatives.

AMGN — Amgen Inc.